Fentanyl transdermal patch recall expanded

Mar 03, 2008

The U.S. Food and Drug Administration announced the expansion of a recall of Fentanyl transdermal system CII patches sold in the United States.

The action by Actavis Inc. expands the company's initial recall of 14 lots of Fentanyl transdermal patches announced Feb. 17. That recall was due to a possible fold-over defect in the product. The expanded recall is a precautionary measure because Actavis lacks assurance all patches are free from defects, the FDA said.

All recalled patches were sold nationwide in the United States. Fentanyl patches sold by Actavis in Europe are not affected by the recall.

The patches are used for the management of persistent, moderate to severe chronic pain.

The FDA said exposure to Fentanyl gel may lead to serious adverse events, including respiratory depression and possible overdose, which might be fatal.

Officials said Actavis was formerly known as Abrika Pharmaceuticals Inc. and some pouches containing the patches may be labeled with an Abrika Pharmaceuticals label.

The lots covered by the recall have expiration dates between May 2009 and December 2009. The FDA said anyone who has Fentanyl patches labeled with an Abrika or Actavis logo should check them for those expiration dates.

Copyright 2008 by United Press International

Explore further: India's meth addiction grows as criminals tap chemical hub

add to favorites email to friend print save as pdf

Related Stories

Fentanyl pain patches are recalled

Feb 18, 2008

The U.S. Food and Drug Administration announced the recall of Fentanyl transdermal system patches due to a potential safety hazard.

Recommended for you

Determine patient preferences by means of conjoint analysis

19 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0